Screening of biomarkers for prediction of multisite artery disease in patients with recent myocardial infarction.
Adult
Aged
Aged, 80 and over
Biomarkers
/ analysis
Cohort Studies
Female
Growth Differentiation Factor 15
/ analysis
Humans
Male
Middle Aged
Myocardial Infarction
/ complications
Peripheral Arterial Disease
/ diagnosis
Receptors, Tumor Necrosis Factor, Type I
/ analysis
Receptors, Tumor Necrosis Factor, Type II
/ analysis
Acute coronary disease
atherosclerosis
biomarkers
multisite artery disease
peripheral artery disease
Journal
Scandinavian journal of clinical and laboratory investigation
ISSN: 1502-7686
Titre abrégé: Scand J Clin Lab Invest
Pays: England
ID NLM: 0404375
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
pubmed:
5
8
2021
medline:
8
3
2022
entrez:
4
8
2021
Statut:
ppublish
Résumé
A few studies have examined biomarkers in patients with myocardial infarction (MI) and peripheral artery disease (PAD), i.e. multisite artery disease (MSAD). The aim of the study was firstly, to associate biomarkers with the occurrence of PAD/MSAD and secondly, if those can, in addition to clinical characteristics, identify MI patients with MSAD.In two prospectively observational studies including unselected patients with recent MI, PAD was defined as an abnormal ankle-brachial index (ABI) score (<0.9 or >1.4). The proximity extension assay (PEA) technique was used, simultaneously analyzing 92 biomarkers with association to cardiovascular disease. Biomarkers were tested for univariate associations with PAD. Random forest was used to identify biomarkers with a higher association to PAD. The additional discriminatory accuracy of adding biomarkers to clinical characteristics was analyzed by the c-statistics. Nine biomarkers were identified as significantly associated with MSAD/PAD in the primary patient cohort, analyzed early after the MI. In the prediction analysis, six biomarkers were identified associated with PAD. Three of these; Tumor necrosis factor receptor (TNFR-1), Tumor necrosis factor receptor 2 (TNFR-2) and Growth Differentiation Factor 15 (GDF-15) improved c-statistics when added to clinical characteristics from 0.683 (95% CI 0.610-0.756) to 0.715 (95% CI 0.645-0.784) in the primary patient cohort with a similar result, 0.729 (95% CI 0.687-0.770) to 0.752 (95% CI 0.771-0.792) in the secondary patient cohort. Biomarkers associated with inflammatory pathways are associated with MSAD in MI patients. Three biomarkers of 92; TNFR-1, TNFR-2 and GDF-15, in this exploratory added information in the prediction of MSAD and emphasis the importance of further studies.
Identifiants
pubmed: 34346268
doi: 10.1080/00365513.2021.1921839
doi:
Substances chimiques
Biomarkers
0
GDF15 protein, human
0
Growth Differentiation Factor 15
0
Receptors, Tumor Necrosis Factor, Type I
0
Receptors, Tumor Necrosis Factor, Type II
0
TNFRSF1A protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM